CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of canc ...
Northwestern Medicine scientists have discovered that specialized immune cells within the glioblastoma tumor metabolize ...
ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T cells directly within the body, bypassing the weeks-long ex vivo ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...
RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...
Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results